Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04578743
Other study ID # ExACTT-2
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date October 1, 2020
Est. completion date September 30, 2021

Study information

Verified date February 2022
Source ANSwers Neuroscience, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a Phase 2, open-label study of a therapeutic intervention (graded exercise)compared to a reference therapy (passive stretching) in patients who have sustained mTBI. Subjects will be randomly assigned with a ratio of 1:1 to complete either graded exercise or passive stretching using a parallel-group design. The effects of graded exercise and passive stretching will be compared using ClearPlay© (ANSwers Neuroscience Pty Ltd commercial mobile application) The study will also validate the performance of two devices: 1. ClearHeart©, ANSwers Neuroscience Pty Ltd commercial prototype for cold pressor testing, compared to ice bucket testing. 2. ClearPlay©, ANSwers Neuroscience Pty Ltd commercial prototype based on the joint position error test to assess "whiplash".


Description:

Study Type: Interventional Estimated Enrollment: 400 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Therapeutic Intervention, Open-Label Study to Compare the Efficacy and Safety of Graded Exercise Compared to Passive Stretching in Subjects Who Have Sustained a Mild Traumatic Brain Injury Estimated Study Start Date: October 1, 2020 Estimated Primary Completion Date: September 30, 2022 Estimated Study Completion Date: September 30, 2023


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 45 Years
Eligibility Inclusion Criteria: 1. Male or female subjects aged =14 to =45, able and willing to provide informed consent (=18 years), or informed consent is obtained by the parent or legal guardian for minor subjects, with the minor providing age appropriate assent, according to local law and regulations; 2. Subject is fluent in English, able to understand and agree to comply with protocol requirements, and complete all assessments; 3. Subject has a history of recent concussion as diagnosed by a health care professional within 3 to 14 days of enrolment; Note: Concussion is defined as a head injury/blow to the head resulting in any of the following 3 signs and/or new symptoms: (1) amnesia for less than 24 hours; (2) Loss of consciousness for less than 30 minutes; (3) Glasgow Coma Scale score > = 13; (4) Dazed and Confused/bell rung; with at least 1 new symptom or augmentation of a previous symptom on the PCSS as compared with baseline at the time of enrolment, including: headaches, dizziness, fatigue, irritability, insomnia, difficulty concentrating, and/or memory difficulties; (5) The composite symptom score on the PCSS must be at least 3 points higher post-concussion than pre-concussion. 4. Subject has daily access to the internet. Exclusion Criteria: 1. History of prior head injury as defined by: 1. An injury/blow to the head within 12 months prior to screening with any associated residual symptoms; 2. An injury/blow to the head within 3 months prior to screening diagnosed as a concussion; 3. An injury/blow to the head within 3 months prior to screening with any of the following symptoms: amnesia, loss of consciousness, dazed and confused/bell rung; 2. Evidence of blood or micro-hemorrhages on prior or current computed tomography scan or magnetic resonance imaging scan if obtained; 3. Diagnosis of a neurological condition including the following: stroke, multiple sclerosis, epilepsy, brain tumor/cancer, encephalitis, dementia, movement disorder, or spontaneous nystagmus; 4. Psychiatric history with any of the following: 1. History of psychiatric hospitalization, history of legal trouble for violence; 2. Requires psychotropic medication other than (1) stable dose of a selective serotonin reuptake inhibitors (SSRI) medication, or (2) stable dose of a tricyclic antidepressants (TCA) medication; 3. Prior diagnosis of psychotic disorder, bipolar disorder, eating disorder, substance abuse disorder; 5. Current use of a beta blocker; 6. History of drug or alcohol dependency or abuse within a year before Screening, by self-report; 7. Two or more the following cardiovascular risk factors: 1. Prior diagnosis of, or currently taking medication for cardiovascular, metabolic or pulmonary conditions; 2. Family history of myocardial infarction, coronary revascularization or sudden death before 55 years; 3. Diagnosis of hypertension; 4. Diagnosis of hyperlipidemia; 5. Subjects with peripheral circulatory disorders; 8. Subjects who are unable or unwilling to exercise for health or personal reasons; 9. Subjects who have musculoskeletal injuries which could make exercise difficult or painful.

Study Design


Intervention

Device:
Graded Exercise Therapy: ClearPlay(TM)
ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.

Locations

Country Name City State
Australia University of Queensland Brisbane Queensland
Australia Royal Prince Alfred Hospital Camperdown New South Wales
Australia Alfred Health Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
ANSwers Neuroscience, Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary ExACTT The primary objective of the study is to compare the effects of graded exercise and passive stretching using ClearPlayTM (ANSwers Neuroscience Pty Ltd commercial mobile application) on recovery following mTBI in the Australian setting. 2 Years
See also
  Status Clinical Trial Phase
Recruiting NCT04372797 - Standardized Instruments to Provide Diagnostic and Prognostic Information in Mild Traumatic Brain Injury (mTBI) N/A
Completed NCT01903525 - DHA For The Treatment of Pediatric Concussion Related to Sports Injury Phase 1
Completed NCT01847040 - Deployment Related Mild Traumatic Brain Injury (mTBI)
Completed NCT03678077 - Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
Recruiting NCT05682677 - Combined Neuromodulation and Cognitive Training for Post-mTBI Depression N/A
Terminated NCT03345550 - OPTIMA-TBI Pilot Study Phase 2
Completed NCT05095012 - RECOVER Clinical Pathway for Pediatric Concussion N/A
Recruiting NCT05886400 - The Effects of Environmental Distractions on SCAT6 Outcomes N/A
Recruiting NCT05262361 - Persistent Post-Concussion Symptoms With Convergence Insufficiency N/A
Active, not recruiting NCT03892291 - Objective Dual-task Turning Measures for Return-to-duty Assessments
Completed NCT03688984 - Treatment of Insomnia for Adolescents With Mild Traumatic Brain Injury N/A
Completed NCT02057081 - Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI N/A
Recruiting NCT06233851 - t-BIOMAP : Prospective Paediatric Cohort Study of Blood Biomarkers in mTBI
Completed NCT02844946 - One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology N/A
Completed NCT04641767 - BIOmarkers of TRAumatic Brain Injury Spain (BIOTRABIS)
Recruiting NCT06112093 - Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches N/A
Recruiting NCT03819608 - Neuromodulation and Neurorehabilitation for mTBI Plus PTSD N/A
Withdrawn NCT00580918 - Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients
Completed NCT03319966 - Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury
Recruiting NCT03846830 - Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation N/A